402 related articles for article (PubMed ID: 24633661)
81. Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how?
Klyuchnikov E; Bacher U; Kroll T; Shea TC; Lazarus HM; Bredeson C; Fenske TS
Bone Marrow Transplant; 2014 Jan; 49(1):1-7. PubMed ID: 23708703
[TBL] [Abstract][Full Text] [Related]
82. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?
Bacher U; Klyuchnikov E; Le-Rademacher J; Carreras J; Armand P; Bishop MR; Bredeson CN; Cairo MS; Fenske TS; Freytes CO; Gale RP; Gibson J; Isola LM; Inwards DJ; Laport GG; Lazarus HM; Maziarz RT; Wiernik PH; Schouten HC; Slavin S; Smith SM; Vose JM; Waller EK; Hari PN;
Blood; 2012 Nov; 120(20):4256-62. PubMed ID: 23007405
[TBL] [Abstract][Full Text] [Related]
83. Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study.
Bento L; Gutiérrez A; Novelli S; Montoro J; Piñana JL; López-Corral L; Cabrero M; Martín-Sancho A; Gutiérrez-García G; Ortiz-Moscovich M; Bastos-Oreiro M; Dorado N; Pérez A; Hernani R; Ferrà C; Parody R; García-Cadenas I; Herrera P; Rodríguez G; Rodríguez N; Martín C; Yáñez L; Zanabili J; Varela MR; López-Godino O; Heras I; Español I; Martínez C; Pérez-Simón JA; Solano C; Sureda A; Sierra J; Sampol A; Caballero D;
Bone Marrow Transplant; 2021 Aug; 56(8):1919-1928. PubMed ID: 33767400
[TBL] [Abstract][Full Text] [Related]
84. Clinical efficacy and safety in relapsed/refractory diffuse large B-cell lymphoma: a systematic literature review.
Colosia A; Njue A; Trask PC; Olivares R; Khan S; Abbe A; Police R; Wang J; Ruiz-Soto R; Kaye JA; Awan F
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):343-355.e6. PubMed ID: 24768510
[TBL] [Abstract][Full Text] [Related]
85. Treatment strategies in patients with AML or high-risk myelodysplastic syndrome relapsed after Allo-SCT.
Sauer T; Silling G; Groth C; Rosenow F; Krug U; Görlich D; Evers G; Albring J; Besoke R; Mesters RM; Müller-Tidow C; Kessler T; Büchner T; Berdel WE; Stelljes M
Bone Marrow Transplant; 2015 Apr; 50(4):485-92. PubMed ID: 25599163
[TBL] [Abstract][Full Text] [Related]
86. Outcome of relapse after allogeneic HSCT in children with ALL enrolled in the ALL-SCT 2003/2007 trial.
Kuhlen M; Willasch AM; Dalle JH; Wachowiak J; Yaniv I; Ifversen M; Sedlacek P; Guengoer T; Lang P; Bader P; Sufliarska S; Balduzzi A; Strahm B; von Luettichau I; Hoell JI; Borkhardt A; Klingebiel T; Schrappe M; von Stackelberg A; Glogova E; Poetschger U; Meisel R; Peters C
Br J Haematol; 2018 Jan; 180(1):82-89. PubMed ID: 29193007
[TBL] [Abstract][Full Text] [Related]
87. Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograft-Allograft in Multiple Myeloma.
Giaccone L; Evangelista A; Patriarca F; Sorasio R; Pini M; Carnevale-Schianca F; Festuccia M; Brunello L; Zallio F; Maffini E; Omedé P; Bringhen S; Mordini N; Fanin R; Ciccone G; Boccadoro M; Bruno B
Biol Blood Marrow Transplant; 2018 Jan; 24(1):189-193. PubMed ID: 28987930
[TBL] [Abstract][Full Text] [Related]
88. Allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphomas: a retrospective analysis of 77 cases.
Picleanu AM; Novelli S; Monter A; Garcia-Cadenas I; Caballero AC; Martino R; Esquirol A; Briones J; Sierra J
Ann Hematol; 2017 May; 96(5):787-796. PubMed ID: 28168350
[TBL] [Abstract][Full Text] [Related]
89. The salvage role of allogeneic hematopoietic stem-cell transplantation in relapsed/refractory diffuse large B cell lymphoma.
Min GJ; Jeon YW; Kim TY; Kwag D; Kim BS; Lee J; Lee JH; Park SS; Park S; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Cho SG
Sci Rep; 2023 Oct; 13(1):17496. PubMed ID: 37840059
[TBL] [Abstract][Full Text] [Related]
90. Outcome of stem cell transplantation for Waldenström's macroglobulinemia: analysis of the Japan Society for Hematopoietic Cell Transplantation (JSHCT) Lymphoma Working Group.
Sakurai M; Mori T; Uchiyama H; Ago H; Iwato K; Eto T; Iwasaki H; Kawata T; Takamatsu H; Yamasaki S; Takanashi M; Ichinohe T; Atsuta Y; Suzuki R
Ann Hematol; 2020 Jul; 99(7):1635-1642. PubMed ID: 32424672
[TBL] [Abstract][Full Text] [Related]
91. High-dose rituximab in combination with autologous stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma.
Shi YF; Zhou SJ; Sun L; Yu K; Chen Y
Med Clin (Barc); 2020 Sep; 155(6):235-241. PubMed ID: 32173075
[TBL] [Abstract][Full Text] [Related]
92. Multimodal treatment with ALL-like chemotherapy, Auto-SCT and radiotherapy for lymphoblastic lymphoma.
Bersvendsen H; Kolstad A; Blystad AK; Aurlien E; Fosså A; Kvaløy SO; Holte H; Lauritzsen GF
Acta Oncol; 2014 May; 53(5):680-7. PubMed ID: 24237392
[TBL] [Abstract][Full Text] [Related]
93. Impact of Routine Surveillance Imaging on Outcomes of Patients With Diffuse Large B-Cell Lymphoma After Autologous Hematopoietic Cell Transplantation.
Epperla N; Shah N; Hamadani M; Richardson K; Kapke JT; Patel A; Teegavarapu SP; Carrum G; Hari PN; Pingali SR; Karmali R; Fenske TS
Clin Lymphoma Myeloma Leuk; 2016 Dec; 16(12):672-678. PubMed ID: 27660080
[TBL] [Abstract][Full Text] [Related]
94. Pre-transplant (18)F-fluorodeoxyglucose positron emission tomography-based survival model in patients with aggressive lymphoma undergoing high-dose chemotherapy and autologous SCT.
Akhtar S; Al-Sugair AS; Abouzied M; Alkadhi Y; Dingle M; Abdelsalam M; Soudy H; Darwish A; Eltigani A; Elhassan TA; Nabil-Ahmed M; Maghfoor I
Bone Marrow Transplant; 2013 Apr; 48(4):551-6. PubMed ID: 22964592
[TBL] [Abstract][Full Text] [Related]
95. [Autologous hematopoietic stem cell transplantation for patients with diffuse large B-cell lymphoma: a retrospective study].
Lu XL; Li Y; Huang WR; Guo YL; Zhao XL; Lu N; Zhu HY; Wang QS; Yu L; Jing Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):617-22. PubMed ID: 23815909
[TBL] [Abstract][Full Text] [Related]
96. Treatment of relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: the Nagasaki Transplant Group experience.
Itonaga H; Tsushima H; Taguchi J; Fukushima T; Taniguchi H; Sato S; Ando K; Sawayama Y; Matsuo E; Yamasaki R; Onimaru Y; Imanishi D; Imaizumi Y; Yoshida S; Hata T; Moriuchi Y; Uike N; Miyazaki Y
Blood; 2013 Jan; 121(1):219-25. PubMed ID: 23100309
[TBL] [Abstract][Full Text] [Related]
97. The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience.
Rohlfing S; Dietrich S; Witzens-Harig M; Hegenbart U; Schönland S; Luft T; Ho AD; Dreger P
Ann Hematol; 2018 Jul; 97(7):1241-1250. PubMed ID: 29549411
[TBL] [Abstract][Full Text] [Related]
98. Safety and efficacy of high-dose cyclophosphamide, etoposide and ranimustine regimen followed by autologous peripheral blood stem cell transplant for patients with diffuse large B-cell lymphoma.
Kobayashi Y; Hatta Y; Sugitani M; Hojo A; Nakagawa M; Kusuda M; Uchino Y; Takahashi H; Kiso S; Hirabayashi Y; Yagi M; Kodaira H; Kurita D; Miura K; Iriyama N; Kobayashi S; Kura Y; Horikoshi A; Sawada U; Takeuchi J; Takei M
Leuk Lymphoma; 2014 Nov; 55(11):2514-9. PubMed ID: 24491027
[TBL] [Abstract][Full Text] [Related]
99. Impact of prior treatment on outcome of transformed follicular lymphoma and relapsed de novo diffuse large B cell lymphoma: a retrospective multicentre analysis.
Lerch K; Meyer AH; Stroux A; Hirt C; Keller U; Viardot A; Marks R; Schreiber S; Pezzutto A; Scholz CW
Ann Hematol; 2015 Jun; 94(6):981-8. PubMed ID: 25645656
[TBL] [Abstract][Full Text] [Related]
100. The role of hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma.
Kako S; Izutsu K; Kato K; Kim SW; Mori T; Fukuda T; Kobayashi N; Taji H; Hashimoto H; Kondo T; Sakamaki H; Morishima Y; Kato K; Suzuki R; Suzumiya J;
Am J Hematol; 2015 Feb; 90(2):132-8. PubMed ID: 25382792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
